Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute, Egypt
Institut Claudius Regaud
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of California, San Francisco
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Kestrel Therapeutics, Inc.
Institut Claudius Regaud
Institut Claudius Regaud
Memorial Sloan Kettering Cancer Center
National Cancer Institute, Naples
University of Maryland, Baltimore
Hospices Civils de Lyon
M.D. Anderson Cancer Center
Alliance for Clinical Trials in Oncology
Icahn School of Medicine at Mount Sinai
Ohio State University Comprehensive Cancer Center
Mayo Clinic
University of Wisconsin, Madison
Nagoya City University
University of Pittsburgh
National Cancer Centre, Singapore
State University of Londrina
The Netherlands Cancer Institute
Assiut University
University of California, San Diego
The Methodist Hospital Research Institute
University of Malaga
Memorial Sloan Kettering Cancer Center
Centre Leon Berard
NRG Oncology
University of Rochester
University of California, San Diego
Shanghai Junshi Bioscience Co., Ltd.
St. Justine's Hospital
M.D. Anderson Cancer Center
Spanish Breast Cancer Research Group
Aarhus University Hospital
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Rutgers, The State University of New Jersey
NRG Oncology
University of California, San Francisco